oncology

Merck & Co.: Keytruda, the 2028 Patent Cliff, and the Post-Cliff Pipeline

Merck & Co. — U.S. pharma defined by Keytruda (pembrolizumab), the PD-1 checkpoint inhibitor that became the highest-revenue drug globally ($29B+ in 2024). 2028 patent cliff approaching. CEO Robert Davis since July 2021.